Search
Trifezolac
go.drugbank.com/drugs/DB21380ExperimentalTrifezolac is a small molecule drug. The usage of the INN stem '-ac' in the name indicates that Trifezolac is a anti-inflammatory agent, ibufenac derivative.
Afizagabar
go.drugbank.com/drugs/DB21439InvestigationalAfizagabar is a small molecule drug. Afizagabar is under investigation in clinical trial NCT02877615 (Efficacy and Safety Trial With S 44819 After Recent Ischemic Cerebral Event).
Pulrodemstat
go.drugbank.com/drugs/DB21497ExperimentalPulrodemstat is a small molecule drug. The usage of the INN stem '-demstat' in the name indicates that Pulrodemstat is a Lysine-specific histone demethylase inhibitor.
Zavolosotine
go.drugbank.com/drugs/DB21531ExperimentalZavolosotine is a small molecule drug. The usage of the INN stem '-sotine' in the name indicates that Zavolosotine is a non-peptidic somatostatin receptor agonist.
Branosotine
go.drugbank.com/drugs/DB21674ExperimentalBranosotine is a small molecule drug. The usage of the INN stem '-sotine' in the name indicates that Branosotine is a non-peptidic somatostatin receptor agonist.
RD06-04
go.drugbank.com/drugs/DB24647InvestigationalRD06-04 is a biologic drug. … RD06-04 is under investigation in clinical trial NCT06986018 (Clinical Study on the Targeted CD19 Universal CAR-T Cell Injection (RD06-04) for the Treatment of IIM and AAV).
Vibostolimab
go.drugbank.com/drugs/DB16420InvestigationalVibostolimab is under investigation in clinical trial NCT04303169 (Substudy 02C: Safety and Efficacy of Pembrolizumab in Combination With Investigational Agents or Pembrolizumab Alone in Participants With
Rocakinogene sifuplasmid
go.drugbank.com/drugs/DB16316InvestigationalRocakinogene sifuplasmid is under investigation in clinical trial NCT03491683 (INO-5401 and INO-9012 Delivered by Electroporation (EP) in Combination With Cemiplimab (REGN2810) in Newly-diagnosed Glioblastoma
Surotomycin
go.drugbank.com/drugs/DB12076InvestigationalIt is a benzenebutanoic acid derivative patented by Cubist Pharmaceuticals, Inc. as antibacterial agents for the treatment of Gram-positive infections. … Surotomycin has a fourfold greater in vitro potency than vancomycin against C.
FT-1101
go.drugbank.com/drugs/DB17553Investigational[A257301] FT-1101 is under investigation in clinical trial NCT02543879 (Study of a Novel BET Inhibitor FT-1101 in Patients With Relapsed or Refractory Hematologic Malignancies). … FT-1101 is a novel Bromodomain and Extra-Terminal motif (BET) inhibitor.